Parker Labs leads investment in Solstice ultrasound contrast agent

By staff writers

July 7, 2021 -- Parker Laboratories has led a consortium making an investment in Solstice Pharmaceuticals that's designed to fund the company's development of a new ultrasound contrast agent.

The agent is based on microbubble technology that allows image contrast to be precisely engineered and optimized with custom-made monodisperse microbubbles for use in a wide range of applications. It aims to enhance image contrast, improve diagnostic accuracy, and make ultrasound scanning more widely applicable.

Parker's investment speeds up the clinical development of the contrast agent. The amount of the investment was not disclosed.

Copyright © 2021

To read this and get access to all of the exclusive content on create a free account or sign-in now.

Member Sign In:
MemberID or Email Address:  
Do you have a password?
No, I want a free membership.
Yes, I have a password:  
Forgot your password?
Sign in using your social networking account:
Sign in using your social networking